Anthony Vendetti

Edward Wu

Evan Greenberg

John Wendell

Michael Samuels

- Daxor Corporation (DXR) has debuted its **newly FDA-cleared, next-generation BVA analyzer**, which offers enhanced ease of use, speed, and over 95% accuracy for data-driven fluid management.  **[27367_e3efee6ffa75402d9cebda3aaebc1ac8_0]** 
- This new analyzer targets a **multi-billion-dollar market** and positions Daxor to capture significant commercial share.  **[27367_e3efee6ffa75402d9cebda3aaebc1ac8_0]** **[27367_e3efee6ffa75402d9cebda3aaebc1ac8_1]** 
- New clinical data presented at the HFSA meeting validated Daxor's BVA technology, demonstrating **zero unplanned hospital admissions** for optimally managed heart failure patients and **improved survival and reduced readmissions** for LVAD patients.  **[27367_e3efee6ffa75402d9cebda3aaebc1ac8_0]** **[27367_e3efee6ffa75402d9cebda3aaebc1ac8_1]**

Daxor Announces FDA Clearance of Next-Generation BVA Analyzer and Clinical Validation

- Daxor Corporation received **FDA Clearance for its new rapid, lightweight Blood Volume Analysis System in August 2025**, which is three times faster, portable, and a fraction of the size of the existing BVA-100.  **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_0]** **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_4]** 
- The operating division experienced a **73 percent increase in unaudited revenues** for the six-month period ended June 30, 2025, compared to the six-month period ended June 30, 2024.  **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_1]** **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_4]** 
- Net Asset Value (NAV) increased to **$7.15 per share** as of June 30, 2025, up **$0.40 per share** from $6.75 per share at June 30, 2024.  **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_1]** **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_4]** 
- Market penetration accelerated with **three new facility adoptions in July 2025** and the BVA diagnostic reaching **two new U.S. Healthcare Systems in May 2025**.  **[27367_bba7be58d75b47c6939f6e8bcbbd0ad7_2]**

DAXOR (DXR)